Role of Ca2+ in the action of adrenocorticotropin in cultured human adrenal glomerulosa cells.
The present report details the role of Ca2+ in the early events of ACTH action in human adrenal glomerulosa cells. Threshold stimulations of both aldosterone and cAMP production were obtained with a concentration of 10 pM ACTH, an ED50 of 0.1 nM, and maximal aldosterone stimulation (5.5-fold increase over control) at 10 nM ACTH. ACTH also induced a sustained increase of intracellular calcium ([Ca2+]i) with maximal stimulation of 1.6 +/- 0.1-fold over control values. This increase does not involve mobilization of calcium from intracellular pools since no response was observed in Ca2+-free medium or in the presence of nifedipine, suggesting the involvement of Ca2+ influx by L-type Ca2+ channels. This was confirmed by patch clamp studies that demonstrated that ACTH stimulates L-type Ca2+ channels. Moreover, the Ca2+ ion is not required for ACTH binding to its receptor, but is essential for sustained cAMP production and aldosterone secretion after ACTH stimulation. These results indicate that, in human adrenal glomerulosa cells, a positive feedback loop between adenylyl cyclase-protein kinase A-Ca2+ channels ensures a slow but sustained [Ca2+]i increase that is responsible for sustained cAMP production and aldosterone secretion.
Gallo-Payet
N
N
Service of Endocrinology, Department of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada.
Grazzini
E
E
Côté
M
M
Chouinard
L
L
Chorvátová
A
A
Bilodeau
L
L
Payet
M D
MD
Guillon
G
G
D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology*; D000328:Adult; D000450:Aldosterone / Q000096:biosynthesis*; D002118:Calcium / Q000494:pharmacology / Q000502:physiology*; D015220:Calcium Channels / Q000502:physiology; D020746:Calcium Channels, L-Type; D002462:Cell Membrane / Q000378:metabolism; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology; D007700:Kinetics; D008854:Microscopy, Electron; D008928:Mitochondria / Q000648:ultrastructure; D009532:Nickel / Q000494:pharmacology; D009543:Nifedipine / Q000494:pharmacology; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D013997:Time Factors; D015384:Zona Glomerulosa / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*
D015220:Calcium Channels; D020746:Calcium Channels, L-Type; D004791:Enzyme Inhibitors; D007546:Isoquinolines; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000450:Aldosterone; C022838:nickel chloride; D009532:Nickel; D000324:Adrenocorticotropic Hormone; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D009543:Nifedipine; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; D002118:Calcium